- Home
- HUMA vs CELC Comparison
HUMA vs CELC Comparison
Compare HUMA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- CELC
- Stock Information
- Founded
- HUMA 2004
- CELC 2011
- Country
- HUMA United States
- CELC United States
- Employees
- HUMA N/A
- CELC N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- HUMA Health Care
- CELC Health Care
- Exchange
- HUMA Nasdaq
- CELC Nasdaq
- Market Cap
- HUMA 367.6M
- CELC 440.0M
- IPO Year
- HUMA N/A
- CELC 2017
- Fundamental
- Price
- HUMA $2.32
- CELC $13.79
- Analyst Decision
- HUMA Strong Buy
- CELC Strong Buy
- Analyst Count
- HUMA 7
- CELC 6
- Target Price
- HUMA $13.00
- CELC $30.67
- AVG Volume (30 Days)
- HUMA 3.2M
- CELC 204.8K
- Earning Date
- HUMA 08-12-2025
- CELC 08-13-2025
- Dividend Yield
- HUMA N/A
- CELC N/A
- EPS Growth
- HUMA N/A
- CELC N/A
- EPS
- HUMA N/A
- CELC N/A
- Revenue
- HUMA $517,000.00
- CELC N/A
- Revenue This Year
- HUMA N/A
- CELC N/A
- Revenue Next Year
- HUMA $896.45
- CELC N/A
- P/E Ratio
- HUMA N/A
- CELC N/A
- Revenue Growth
- HUMA N/A
- CELC N/A
- 52 Week Low
- HUMA $1.15
- CELC $7.58
- 52 Week High
- HUMA $9.79
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- HUMA 50.18
- CELC 65.10
- Support Level
- HUMA $2.08
- CELC $12.48
- Resistance Level
- HUMA $2.40
- CELC $13.60
- Average True Range (ATR)
- HUMA 0.14
- CELC 0.77
- MACD
- HUMA -0.03
- CELC 0.10
- Stochastic Oscillator
- HUMA 52.63
- CELC 93.32
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.